Use of magnetization transfer contrast MRI to detect early molecular pathology in alzheimer's disease

Magnetic Resonance in Medicine

Volumn 71, Issue 1, 2014, Pages 333-338

  Pérez Torres, Carlos J ^a   Reynolds, Julia O ^a   Pautler, Robia G ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; amyloid beta; magnetization transfer; MRI

Indexed keywords

GLYCOPROTEINS; MACROMOLECULES; MAGNETIC RESONANCE IMAGING; MAGNETIZATION; PATHOLOGY;

ALZHEIMER'S DISEASE; ALZHEIMER'S DISEASE PATHOLOGIES; AMYLOID BETAS; ANTIOXIDANT THERAPIES; LEARNING AND MEMORY; MAGNETIZATION TRANSFER; MAGNETIZATION TRANSFER CONTRASTS; NEURODEGENERATION;

NEURODEGENERATIVE DISEASES;

AMYLOID BETA PROTEIN; ANTIOXIDANT; TAU PROTEIN;

AGED; ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; IMAGE ANALYSIS; LEARNING DISORDER; MEMORY DISORDER; MOLECULAR PATHOLOGY; MOUSE; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PROTEIN PHOSPHORYLATION; TAUOPATHY;

ALZHEIMER'S DISEASE; AMYLOID BETA; MAGNETIZATION TRANSFER; MRI;

ALZHEIMER DISEASE; AMYLOIDOGENIC PROTEINS; ANIMALS; BRAIN; CONTRAST MEDIA; MAGNETIC RESONANCE IMAGING; MICE; MICE, TRANSGENIC; PATHOLOGY, MOLECULAR; TAU PROTEINS; TISSUE DISTRIBUTION;

EID: 84890788589     PISSN: 07403194     EISSN: 15222594     Source Type: Journal    
DOI: 10.1002/mrm.24665     Document Type: Article

References (45)

1. Alzheimer's Association. 2011 Alzheimer's disease facts and figures. Alzheimers Dement 2011; 7: 208-244.
2. Laakso MP, Soininen H, Partanen K, Helkala EL, Hartikainen P, Vainio P, Hallikainen M, Hänninen T, Riekkinen PJ Sr,. Volumes of hippocampus, amygdala and frontal lobes in the MRI-based diagnosis of early Alzheimer's disease: correlation with memory functions. J Neural Transm Park Dis Dement Sect 1995; 9: 73-86.
3. Tondelli M, Wilcock GK, Nichelli P, De Jager CA, Jenkinson M, Zamboni G,. Structural MRI changes detectable up to ten years before clinical Alzheimer's disease. Neurobiol Aging 2012; 33: 825.e25-825.e36.
4. Querfurth HW, LaFerla FM,. Alzheimer's disease. N Engl J Med 2010; 362: 329-344.
5. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol 2004; 55: 306-319.
6. Benveniste H, Einstein G, Kim KR, Hulette C, Johnson GA,. Detection of neuritic plaques in Alzheimer's disease by magnetic resonance microscopy. Proc Natl Acad Sci USA 1999; 96: 14079-14084.
7. Poduslo JF, Wengenack TM, Curran GL, Wisniewski T, Sigurdsson EM, Macura SI, Borowski BJ, Jack CR,. Molecular targeting of Alzheimer's amyloid plaques for contrast-enhanced magnetic resonance imaging. Neurobiol Dis 2002; 11: 315-329.
8. Wadghiri YZ, Sigurdsson EM, Sadowski M, et al. Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging. Magn Reson Med 2003; 50: 293-302.
9. Yang J, Wadghiri YZ, Hoang DM, Tsui W, Sun Y, Chung E, Li Y, Wang A, de Leon M, Wisniewski T,. Detection of amyloid plaques targeted by USPIO-A[beta]1-42 in Alzheimer's disease transgenic mice using magnetic resonance microimaging. Neuroimage 2011; 55: 1600-1609.
10. Petiet A, Santin M, Bertrand A, et al. Gadolinium-staining reveals amyloid plaques in the brain of Alzheimer's transgenic mice. Neurobiol Aging 2012; 33: 1533-1544.
11. Shankar GM, Li S, Mehta TH, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008; 14: 837-842.
12. Fukumoto H, Tennis M, Locascio JJ, Hyman BT, Growdon JH, Irizarry MC,. Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch Neurol 2003; 60: 958-964.
13. van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MM,. Plasma AB1-40 and AB1-42 and the risk of dementia: a prospective case-cohort study. Lancet Neurol 2006; 5: 655-660.
14. Van Nostrand WE, Wagner SL, Shankle WR, Farrow JS, Dick M, Rozemuller JM, Kuiper MA, Wolters EC, Zimmerman J, Cotman CW,. Decreased levels of soluble amyloid beta-protein precursor in cerebrospinal fluid of live Alzheimer disease patients. Proc Natl Acad Sci USA 1992; 89: 2551-2555.
15. Kester MI, Scheffer PG, Koel-Simmelink MJ, et al. Serial CSF sampling in Alzheimer's disease: specific versus non-specific markers. Neurobiol Aging 2012; 33: 1591-1598.
16. Bateman RJ, Xiong C, Benzinger TLS, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. New Engl J Med 2012; 367: 795-804.
17. Thal DR, Rüb U, Orantes M, Braak H,. Phases of Aβ-deposition in the human brain and its relevance for the development of AD. Neurology 2002; 58: 1791-1800.
18. Braak H, Braak E,. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239-259.
19. Jucker M, Walker LC,. Pathogenic protein seeding in alzheimer disease and other neurodegenerative disorders. Ann Neurol 2011; 70: 532-540.
20. Wolff SD, Balaban RS,. Magnetization transfer contrast (MTC) and tissue water proton relaxation in vivo. Magn Reson Med 1989; 10: 135-144.
21. Horsfield MA,. Magnetization transfer imaging in multiple sclerosis. J Neuroimaging 2005; 15: 58S-67S.
22. Henkelman RM, Stanisz GJ, Graham SJ,. Magnetization transfer in MRI: a review. NMR Biomed 2001; 14: 57-64.
23. Perl DP,. Neuropathology of Alzheimer's disease. Mt Sinai J Med 2010; 77: 32-42.
24. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G,. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996; 274: 99-102.
25. Tomidokoro Y, Harigaya Y, Matsubara E, Ikeda M, Kawarabayashi T, Shirao T, Ishiguro K, Okamoto K, Younkin SG, Shoji M,. Brain Aβ amyloidosis in APPsw mice induces accumulation of presenilin-1 and tau. J Pathol 2001; 194: 500-506.
26. Tomidokoro Y, Ishiguro K, Harigaya Y, Matsubara E, Ikeda M, Park J-M, Yasutake K, Kawarabayashi T, Okamoto K, Shoji M,. Aβ amyloidosis induces the initial stage of tau accumulation in APPSw mice. Neurosci Lett 2001; 299: 169-172.
27. Melov S, Adlard PA, Morten K, Johnson F, Golden TR, et al. Mitochondrial oxidative stress causes hyperphosphorylation of Tau. PLoS One 2007; 2: e536.
28. Massaad CA, Amin SK, Hu L, Mei Y, Klann E, et al. Mitochondrial superoxide contributes to blood flow and axonal transport deficits in the Tg2576 mouse model of Alzheimer's disease. PLoS One 2010; 5: e10561.
29. Neelima BC,. Effect of aged garlic extract on APP processing and tau phosphorylation in Alzheimer's transgenic model Tg2576. J Ethnopharmacol 2006; 108: 385-394.
30. Massaad CA, Washington TM, Pautler RG, Klann E,. Overexpression of SOD-2 reduces hippocampal superoxide and prevents memory deficits in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2009; 106: 13576-13581.
31. Ho Y-S, Vincent R, Dey MS, Slot JW, Crapo JD,. Transgenic models for the study of lung antioxidant defense: enhanced manganese-containing superoxide dismutase activity gives partial protection to B6C3 hybrid mice exposed to hyperoxia. Am J Respir Cell Mol Biol 1998; 18: 538-547.
32. Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG,. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci 2001; 21: 372-381.
33. Westerman MA, Cooper-Blacketer D, Mariash A, Kotilinek L, Kawarabayashi T, Younkin LH, Carlson GA, Younkin SG, Ashe KH,. The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J Neurosci 2002; 22: 1858-1867.
34. Arendash GW, Gordon MN, Diamond DM, Austin LA, Hatcher JM, Jantzen P, DiCarlo G, Wilcock D, Morgan D,. Behavioral assessment of Alzheimer's transgenic mice following long-term Abeta vaccination: task specificity and correlations between Abeta deposition and spatial memory. DNA Cell Biol 2001; 20: 737-744.
35. King DL, Arendash GW,. Behavioral characterization of the Tg2576 transgenic model of Alzheimer's disease through 19 months. Physiol Behav 2002; 75: 627-642.
36. Chapman PF, White GL, Jones MW, et al. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat Neurosci 1999; 2: 271-276.
37. Smith KDB, Kallhoff V, Zheng H, Pautler RG,. In vivo axonal transport rates decrease in a mouse model of Alzheimer's disease. NeuroImage 2007; 35: 1401-1408.
38. Townsend M, Qu Y, Gray A, Wu Z, Seto T, Hutton M, Shearman MS, Middleton RE,. Oral treatment with a γ-secretase inhibitor improves long-term potentiation in a mouse model of Alzheimer's disease. J Pharmacol Exp Ther 2010; 333: 110-119.
39. Terai K, Iwai A, Kawabata S, Sasamata M, Miyata K, Yamaguchi T,. Apolipoprotein E deposition and astrogliosis are associated with maturation of β-amyloid plaques in βAPPswe transgenic mouse: implications for the pathogenesis of Alzheimer's disease. Brain Res 2001; 900: 48-56.
40. Kumar-Singh S, Pirici D, McGowan E, Serneels S, Ceuterick C, Hardy J, Duff K, Dickson D, Van Broeckhoven C,. Dense-core plaques in Tg2576 and PSAPP mouse models of Alzheimer's disease are centered on vessel walls. Am J Pathol 2005; 167: 527-543.
41. Lindwall G, Cole RD,. Phosphorylation affects the ability of tau protein to promote microtubule assembly. J Biol Chem 1984; 259: 5301-5305.
42. Janus C,. Conditionally inducible tau mice-designing a better mouse model of neurodegenerative diseases. Genes Brain Behav 2008; 7: 12-27.
43. Maccioni RB, Farías G, Morales I, Navarrete L,. The revitalized tau hypothesis on Alzheimer's disease. Arch Med Res 2010; 41: 226-231.
44. Ridha BH, Symms MR, Tozer DJ, et al. Magnetization transfer ratio in Alzheimer disease: comparison with volumetric measurements. Am J Neuroradiol 2007; 28: 965-970.
45. Ginestroni A, Battaglini M, Della Nave R, et al. Early structural changes in individuals at risk of familial Alzheimer's disease: a volumetry and magnetization transfer MR imaging study. J Neurol 2009; 256: 925-932.